.jpg)
FDA adcomm narrowly votes against UroGen’s bladder cancer drug
The FDA's Oncologic Drugs Advisory Committee on Wednesday voted 5 to 4 against UroGen Pharma's mitomycin as an option for low-grade intermediate-risk non-muscle invasive bladder cancer. Panelists and FDA speakers generally agreed that UroGen should ...
The FDA's Oncologic Drugs Advisory Committee on Wednesday voted 5 to 4 against UroGen Pharma's mitomycin as an option for low-grade intermediate-risk non-muscle invasive bladder cancer.
Panelists and FDA speakers generally agreed that UroGen should ...
